Worldwide Study Finder

Phase 4WithdrawnINTERVENTIONAL

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

ClinicalTrials.gov · NCT00759083 · Registry updated: 2020-10-19

Condition / research focus: Heparin-Induced Thrombocytopenia; Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Sponsor: The Medicines Company
Countries with listed sites: United States
Registry dates and results: Start: 2008-09. Completion: 2010-05-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bivalirudin (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Duke Clinical Research Institute
Durham, North Carolina, United States

Phase 3UnknownINTERVENTIONAL

Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms

ClinicalTrials.gov · NCT04532333 · Registry updated: 2020-08-31

Condition / research focus: Subarachnoid Hemorrhage, Aneurysmal
Sponsor: Changhai Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2020-08. Completion: 2021-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin 250 MG Injection (drug)
Heparin (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial

ClinicalTrials.gov · NCT04445935 · Registry updated: 2020-06-24

Condition / research focus: Anticoagulation in COVID-19 ARDS
Sponsor: Hamad Medical Corporation
Countries with listed sites: Qatar
Registry dates and results: Start: 2020-06-28. Completion: 2021-03-28 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin Injection (drug) — also listed as: anticoagulation
Standard treatment (drug)

Where the study takes place — 1 listed sites

Hamad Medical Corporation
Doha, Qatar
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion

ClinicalTrials.gov · NCT04195997 · Registry updated: 2019-12-12

Condition / research focus: Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk
Sponsor: Shanghai Zhongshan Hospital
Countries with listed sites: China
Registry dates and results: Start: 2020-02-01. Completion: 2021-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug)
Heparin (drug)

Where the study takes place — 1 listed sites

Zhongshan Hopital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Bivalirudin in Late PCI for Oatients With STEMI

ClinicalTrials.gov · NCT04185077 · Registry updated: 2019-12-10

Condition / research focus: STEMI - ST Elevation Myocardial Infarction
Sponsor: Second Xiangya Hospital of Central South University
Countries with listed sites: No country reported
Registry dates and results: Start: 2019-11-30. Completion: 2020-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug) — also listed as: Direct thrombin inhibitor
Heparin (drug) — also listed as: unfractionated heparin

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.

ClinicalTrials.gov · NCT04046029 · Registry updated: 2019-08-06

Condition / research focus: Acute Coronary Syndrome; Percutaneous Coronary Intervention; Aging; Anticoagulants and Bleeding Disorders
Sponsor: The First Affiliated Hospital of Dalian Medical University
Countries with listed sites: China
Registry dates and results: Start: 2019-07-08. Completion: 2021-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug)
Heparin (drug)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Dalian Medical University
Dalian, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

ClinicalTrials.gov · NCT03965208 · Registry updated: 2019-05-28

Condition / research focus: Extracorporeal Membrane Oxygenation Complication; Anticoagulants
Sponsor: Legacy Health System
Countries with listed sites: United States
Registry dates and results: Start: 2019-05-23. Completion: 2020-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug) — also listed as: Angiomax
Unfractionated heparin (drug)

Where the study takes place — 1 listed sites

Legacy Health System
Portland, Oregon, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Anticoagulant Treatments and Percutaneous Coronary Angioplasty

ClinicalTrials.gov · NCT00669149 · Registry updated: 2019-05-17

Condition / research focus: Coronary Artery Disease
Sponsor: Centre Hospitalier de PAU
Countries with listed sites: France
Registry dates and results: Start: 2008-06. Completion: 2013-08-03 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

clopidogrel + aspirin (drug) — also listed as: Plavix Kardégic
heparin + clopidogrel + aspirin (drug) — also listed as: héparine Choay Plavix Kardégic
enoxaparin + clopidogrel + aspirin (drug) — also listed as: Lovenox Plavix Kardégic
bivalirudin + clopidogrel + aspirin (drug) — also listed as: Angiox Plavix Kardégic

Where the study takes place — 1 listed sites

Centre Hospitalier de Pau
Pau, Pyrénées-Atlantiques, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction

ClinicalTrials.gov · NCT03882775 · Registry updated: 2019-03-20

Condition / research focus: STEMI; Percutaneous Coronary Intervention; Aged
Sponsor: The First Affiliated Hospital of Dalian Medical University
Countries with listed sites: China
Registry dates and results: Start: 2019-01-16. Completion: 2020-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug)
Heparin (drug)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

ClinicalTrials.gov · NCT00073580 · Registry updated: 2018-11-30

Condition / research focus: Thrombocytopenia; Thrombosis; Cardiac Disease; Coronary Artery Bypass Surgery
Sponsor: The Medicines Company
Countries with listed sites: United States
Registry dates and results: Start: 2003-10. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Angiomax (bivalirudin) anticoagulant (drug) — also listed as: bivalirudin

Where the study takes place — 1 listed sites

The Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Bivalirudin Infusion for Ventricular Infarction Limitation

ClinicalTrials.gov · NCT02565147 · Registry updated: 2018-10-05

Condition / research focus: Acute Myocardial Infarction
Sponsor: The Medicines Company
Countries with listed sites: France · Netherlands
Registry dates and results: Start: 2014-12-19. Completion: 2016-06-14 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PPCI (procedure)
Bivalirudin (drug) — also listed as: Angiomax, Angiox
Heparin (drug) — also listed as: UFH

Where the study takes place — 4 listed sites

Hopital Ambroise Paré
Boulogne, France
Site recruitment: Not reported
Hospital Lariboisière
Paris, France
Site recruitment: Not reported
VUMC Amsterdam
Amsterdam, Netherlands
Site recruitment: Not reported
Erasmus Medical Center
Rotterdam, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)

ClinicalTrials.gov · NCT03567408 · Registry updated: 2018-08-20

Condition / research focus: Coronary Heart Disease
Sponsor: Qian Gong
Countries with listed sites: No country reported
Registry dates and results: Start: 2018-09-15. Completion: 2020-08-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Selective PCI (procedure)
Bivalirudin (drug) — also listed as: Angiomax

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI

ClinicalTrials.gov · NCT03182855 · Registry updated: 2018-06-28

Condition / research focus: Acute Coronary Syndrome; Myocardial Infarction; STEMI - ST Elevation Myocardial Infarction
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-09-01. Completion: 2019-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ticagrelor (drug) — also listed as: Brilique, Brilinta
Cangrelor Tetrasodium (drug) — also listed as: Kengrexal, Kengreal

Where the study takes place — 1 listed sites

Aarhus University Hospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

ClinicalTrials.gov · NCT02448550 · Registry updated: 2018-05-24

Condition / research focus: Percutaneous Coronary Intervention
Sponsor: Kaiser Permanente
Countries with listed sites: United States
Registry dates and results: Start: 2015-05. Completion: 2016-06-16 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug)
Unfractionated heparin (drug)

Where the study takes place — 1 listed sites

Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

ClinicalTrials.gov · NCT01245725 · Registry updated: 2018-03-13

Condition / research focus: Myocardial Infarction; Acute Coronary Syndromes; Unstable Angina; Percutaneous Coronary Intervention
Sponsor: Medicure
Countries with listed sites: No country reported
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirofiban (Aggrastat) (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding

ClinicalTrials.gov · NCT01084993 · Registry updated: 2018-01-31

Condition / research focus: Coronary Artery Disease
Sponsor: Laval University
Countries with listed sites: Canada
Registry dates and results: Start: 2010-03. Completion: 2019-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug) — also listed as: Angiomax
Heparin (drug)

Where the study takes place — 1 listed sites

Quebec Heart-Lung Institute
Québec, Quebec, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

ClinicalTrials.gov · NCT00433966 · Registry updated: 2017-12-04

Condition / research focus: Myocardial Infarction
Sponsor: Cardiovascular Research Foundation, New York
Countries with listed sites: United States
Registry dates and results: Start: 2005-03. Completion: 2010-11 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug) — also listed as: Angiomax
Unfractionated heparin (drug) — also listed as: Heparin Sodium
Bare metal stent (device) — also listed as: EXPRESS2™
Paclitaxel-eluting stent (device) — also listed as: TAXUS™

Where the study takes place — 1 listed sites

LeBauer CV Research Foundation
Greensboro, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

ClinicalTrials.gov · NCT01913483 · Registry updated: 2017-05-30

Condition / research focus: Peripheral Endovascular Interventions; Bleeding
Sponsor: The Medicines Company
Countries with listed sites: United States
Registry dates and results: Start: 2013-09-24. Completion: 2016-03-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug) — also listed as: AngioMAX, Angiox
Unfractionated Heparin (drug) — also listed as: Heparin

Where the study takes place — 39 listed sites

Tri-Lakes Research
Hot Springs, Arkansas, United States
Site recruitment: Not reported
Stanford Hospital and Clinics
Stanford, California, United States
Site recruitment: Not reported
Clearwater Cardiovascular and Interventional Consultants
Clearwater, Florida, United States
Site recruitment: Not reported
Florida Research Network
Gainesville, Florida, United States
Site recruitment: Not reported
The Cardiac and Vascular Institute
Gainesville, Florida, United States
Site recruitment: Not reported
Baptist Cardiac & Vascular Institute
Miami, Florida, United States
Site recruitment: Not reported
Florida Hospital
Orlando, Florida, United States
Site recruitment: Not reported
Peoria Radiology Research & Education Foundation
Peoria, Illinois, United States
Site recruitment: Not reported
Midwest Cardiovascular Research Foundation
Davenport, Iowa, United States
Site recruitment: Not reported
Kentucky Heart Foundation - King's Daughters Medical Center
Ashland, Kentucky, United States
Site recruitment: Not reported
Tufts Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
VA Boston Healthcare System
Boston, Massachusetts, United States
Site recruitment: Not reported
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Cape Cod Research Institute
Hyannis, Massachusetts, United States
Site recruitment: Not reported
Michigan Heart
Ypsilanti, Michigan, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
Deborah Heart and Lung Center
Browns Mills, New Jersey, United States
Site recruitment: Not reported
Holy Name Medical Center
Teaneck, New Jersey, United States
Site recruitment: Not reported
New Mexico Heart Institute
Albuquerque, New Mexico, United States
Site recruitment: Not reported
Weill Cornell Medical College
New York, New York, United States
Site recruitment: Not reported
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Site recruitment: Not reported
Columbia University Medical Center
New York, New York, United States
Site recruitment: Not reported
Stony Brook Medicine
Stony Brook, New York, United States
Site recruitment: Not reported
Novant Health Heart and Vascular Institute
Charlotte, North Carolina, United States
Site recruitment: Not reported
LeBauer Cardiovascular Research Foundation
Greensboro, North Carolina, United States
Site recruitment: Not reported
University of Cincinnati
Cincinnati, Ohio, United States
Site recruitment: Not reported
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site recruitment: Not reported
Jobst Vascular Institute
Toledo, Ohio, United States
Site recruitment: Not reported
Integris - Baptist Medical Center
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Rhode Island Hospital
Providence, Rhode Island, United States
Site recruitment: Not reported
AnMed Health
Anderson, South Carolina, United States
Site recruitment: Not reported
Medical University of South Carolina
Charleston, South Carolina, United States
Site recruitment: Not reported
Texas Tech University Health Science Center
Lubbock, Texas, United States
Site recruitment: Not reported
Scott and White Hospital
Temple, Texas, United States
Site recruitment: Not reported
Alpine Research
Ogden, Utah, United States
Site recruitment: Not reported
INOVA Alexandria Hospital
Alexandria, Virginia, United States
Site recruitment: Not reported
University of Virginia Health System
Charlottesville, Virginia, United States
Site recruitment: Not reported
Swedish Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

ClinicalTrials.gov · NCT02311231 · Registry updated: 2017-05-19

Condition / research focus: ST-segment Elevation Myocardial Infarction; Non ST-segment Elevation Myocardial Infarction
Sponsor: Uppsala University
Countries with listed sites: Sweden
Registry dates and results: Start: 2014-06. Completion: 2017-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bivalirudin (drug) — also listed as: Angiox
Heparin (drug) — also listed as: Heparin 5000 IU/ml i.v. ,Leo Pharma

Where the study takes place — 1 listed sites

Lund University
Lund, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

ClinicalTrials.gov · NCT01651780 · Registry updated: 2017-04-07

Condition / research focus: Severe Aortic Stenosis; Transcatheter Aortic Valve Replacement; Aortic Valve Replacement
Sponsor: The Medicines Company
Countries with listed sites: Canada · France · Germany · Italy · Netherlands · Switzerland · United Kingdom
Registry dates and results: Start: 2012-10. Completion: 2015-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bivalirudin (drug) — also listed as: AngioMAX, Angiox
Unfractionated Heparin (drug) — also listed as: Heparin

Where the study takes place — 33 listed sites

Montreal Heart Institute
Montreal, Quebec, Canada
Site recruitment: Not reported
St. Paul´s Hospital Providence Health Care
Vancouver, Canada
Site recruitment: Not reported
Clinique Pasteur, Unité de Cardiologie Interventionnelle
Toulouse, Cedex 3, France
Site recruitment: Not reported
CHU de Toulouse
Toulouse, Cedex 9, France
Site recruitment: Not reported
CHU Jean Minjoz, Service de Cardiologie
Besançon, France
Site recruitment: Not reported
Centre Hospitalier de Lyon
Bron, France
Site recruitment: Not reported
Department of Cardiology, CHRU Lille
Lille, France
Site recruitment: Not reported
Institut Hospitalier Jacques Cartier
Massy, France
Site recruitment: Not reported
Service de Cardiologie, Centre Hospitalo-Universitaire, Hôpital Charles-Nicolle
Rouen, France
Site recruitment: Not reported
University Heart Centre, Clinic of Inner Medicine 1 Cardiology
Jena, Lobeda Ost, Germany
Site recruitment: Not reported
Universitätsklinikum Bonn
Bonn, Germany
Site recruitment: Not reported
Klinikum links der Weser Bremen
Bremen, Germany
Site recruitment: Not reported
Elisabeth-Krankenhaus Essen
Essen, Germany
Site recruitment: Not reported
Freiburg University
Freiburg im Breisgau, Germany
Site recruitment: Not reported
Asklepios St. Georg Hamburg
Hamburg, Germany
Site recruitment: Not reported
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Site recruitment: Not reported
Medizinische Hochschule Hannover
Hanover, Germany
Site recruitment: Not reported
Universität Leipzig - Herzzentrum GmbH
Leipzig, Germany
Site recruitment: Not reported
Universitätsmedizin der Johannes Gutenberg-Universitat Mainz
Mainz, Germany
Site recruitment: Not reported
LMU Munich, Klinikum der Universität München
Munich, Germany
Site recruitment: Not reported
Deutsches Herzzentrum München
München, Germany
Site recruitment: Not reported
Helios Heart Center Siegburg
Siegburg, Germany
Site recruitment: Not reported
Ferraroto Hospital, University of Catania
Catania, Italy
Site recruitment: Not reported
Ospedale San Raffaele U.O. Cardiologia Interventistica
Milan, Italy
Site recruitment: Not reported
Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy
Site recruitment: Not reported
Azienda Ospedaliera San Camillo-Forlanini
Roma, Italy
Site recruitment: Not reported
Policlinico Umberto I, Università La Sapienza
Roma, Italy
Site recruitment: Not reported
St. Antonius Ziekenhuis
Nieuwegein, Netherlands
Site recruitment: Not reported
University Medical Center Utrecht
Utrecht, Netherlands
Site recruitment: Not reported
Cardiology University Hospital Basel
Basel, Switzerland
Site recruitment: Not reported
Universitätsklinik Bern
Bern, Switzerland
Site recruitment: Not reported
The Royal Sussex County Hospital
Brighton, East Sussex, United Kingdom
Site recruitment: Not reported
Hammersmith Hospital
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Explore the world’s study registries

Worldwide

Africa

Americas

Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms

Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial

Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion

Bivalirudin in Late PCI for Oatients With STEMI

Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

Anticoagulant Treatments and Percutaneous Coronary Angioplasty

Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Bivalirudin Infusion for Ventricular Infarction Limitation

Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)

Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

Asia

Middle East

Europe

Oceania